New nanotech weapon takes aim at hard-to-treat breast cancer

Breast cancer in its various forms affects more than 250,000 Americans a year. One particularly aggressive and hard-to-treat type is triple-negative breast cancer (TNBC), which lacks specific receptors targeted by existing treatments. The rapid growth and metastasis of this cancer also make it challenging to manage, leading to limited therapy options and an often poor prognosis for patients. Senescent cancer cells are those that, after exposure to chemotherapy, stop multiplying and are resistant to further treatment. Nanotubes with ABT-263 effectively killed senescent cancer cells, making them more susceptible to further treatment from doxorubicin.